Oleg Krijanovski, MD
Hematology & Oncology · Berkeley, CANPI 1841376704
Payments from drug & device makers
Across 380 payments — averaging $1758.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$219K
- Incyte Corporation$172K
- AbbVie$54K
- E.r. Squibb & Sons, L.L.C.$48K
- Bristol Myers Squibb$34K
- Morphosys AG$30K
- plus $111K from 27 others
Across 1 payment — averaging $1455.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Consulting fees$30,55318%
- Speaking & faculty fees$118,14669%
- Travel & lodging$16,57910%
- Food & beverage$6,4114%
- Education$2780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $219,082 |
| Incyte Corporation | 152 | $171,707 |
| AbbVie | 16 | $54,336 |
| E.r. Squibb & Sons, L.L.C. | 14 | $47,608 |
| Bristol Myers Squibb | 20 | $34,248 |
| Morphosys AG | 4 | $30,106 |
| Eli Lilly | 2 | $24,187 |
| Amgen | 25 | $20,108 |
| Genentech, Inc. | 1 | $19,800 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $12,798 |
| Janssen Research & Development, LLC | 1 | $12,500 |
| Johnson & Johnson(2 entities) | 34 | $8,097 |
| CTI Biopharma Corp. | 6 | $5,654 |
| AstraZeneca(2 entities) | 13 | $3,581 |
| Genmab U.S., Inc. | 4 | $1,529 |
| Rigel Pharmaceuticals, Inc. | 3 | $1,040 |
| Bayer | 4 | $991 |
| Pfizer | 12 | $233 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $110 |
| ADC Therapeutics America, Inc. | 1 | $100 |
| Taiho Oncology, Inc. | 4 | $90 |
| Merck | 5 | $85 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Boehringer Ingelheim | 2 | $47 |
| Tesaro, Inc. | 2 | $41 |
| Agios Pharmaceuticals, Inc. | 2 | $34 |
| Gilead(2 entities) | 2 | $32 |
| Seagen Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $22 |
| Exelixis Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$668,346 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 33 | $758,559 |
| PromactaEltrombopag Olamine | 39 | $712,645 |
| BrukinsaZanubrutinib | 48 | $663,639 |
| ImbruvicaIbrutinib | 35 | $562,858 |
| VenclextaVenetoclax | 42 | $557,222 |
| Lenalidomide | 33 | $476,470 |
| JakafiRuxolitinib Phosphate | 26 | $468,167 |
| RevlimidLenalidomide | 25 | $462,134 |
| TagrissoOsimertinib Mesylate | 25 | $404,629 |
| CalquenceAcalabrutinib Maleate | 21 | $317,791 |
| GilotrifAfatinib Dimaleate | 11 | $122,414 |
| EliquisApixaban | 136 | $95,315 |
| Imatinib Mesylate | 14 | $50,714 |
| XareltoRivaroxaban | 57 | $49,354 |
| Atovaquone | 22 | $8,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $47,608 | $758,55933 claims |
| AstraZenecaTagrisso, Calquence | $3,581 | $722,42146 claims |
| NovartisPromacta | $219,082 | $712,64539 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $110 | $562,85835 claims |
| AbbVieVenclexta | $54,336 | $557,22242 claims |
| Incyte CorporationJakafi | $171,707 | $468,16726 claims |
| Bristol Myers SquibbRevlimid | $34,248 | $462,13425 claims |
| Boehringer IngelheimGilotrif | $47 | $122,41411 claims |
| PfizerEliquis | $233 | $95,315136 claims |
| Johnson & JohnsonXarelto | $8,097 | $49,35457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Berkeley
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
- Rana McKaySan Diego$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.